Biomay AG completes capital increase in the amount of €2.8 million from existing investors

Biomay announced today that the company has successfully completed a capital increase in the amount of €2.8 million with participation from most of the existing shareholders. This capital increase brings the number of outstanding shares to 20 million. The fresh capital will be employed to complete the ongoing phase IIb studies with lead product BM32, an innovative grass pollen vaccine and advance its pipeline products to full preclinical development.

Rainer Henning, CEO of Biomay commented: „We are very grateful to our shareholders, which again have demonstrated their long term commitment to the company and their faith in the successful development of our breakthrough products“.

About Biomay:
Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)